Nivolumab + Ipilimumab + Oxaliplatin + Capecitabine + Leucovorin + Fluorouracil
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
Trial Timeline
Oct 12, 2016 → Jun 6, 2024
NCT ID
NCT02872116About Nivolumab + Ipilimumab + Oxaliplatin + Capecitabine + Leucovorin + Fluorouracil
Nivolumab + Ipilimumab + Oxaliplatin + Capecitabine + Leucovorin + Fluorouracil is a phase 3 stage product being developed by Ono Pharmaceutical for Gastric Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02872116. Target conditions include Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Cancer were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02872116 | Phase 3 | Completed |
Competing Products
20 competing products in Gastric Cancer